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C E L L  B I O L O G Y
A stapled peptide mimetic of the CtIP tetramerization 
motif interferes with double-strand break repair 
and replication fork protection
Anika Kuster1, Nour L. Mozaffari1, Oliver J. Wilkinson2, Jessica L. Wojtaszek3,  
Christina Zurfluh1, Sara Przetocka1, Dawid Zyla4, Christine von Aesch1, Mark S. Dillingham2, 
R. Scott Williams3, Alessandro A. Sartori1*
Cancer cells display high levels of DNA damage and replication stress, vulnerabilities that could be exploited by  
drugs targeting DNA repair proteins. Human CtIP promotes homology-mediated repair of DNA double-strand 
breaks (DSBs) and protects stalled replication forks from nucleolytic degradation, thus representing an attractive 
candidate for targeted cancer therapy. Here, we establish a peptide mimetic of the CtIP tetramerization motif 
that inhibits CtIP activity. The hydrocarbon-stapled peptide encompassing amino acid residues 18 to 28 of CtIP 
(SP18–28) stably binds to CtIP tetramers in vitro and facilitates their aggregation into higher-order structures. 
Efficient intracellular uptake of SP18–28 abrogates CtIP localization to damaged chromatin, impairs DSB repair, 
and triggers extensive fork degradation. Moreover, prolonged SP18–28 treatment causes hypersensitivity to 
DNA-damaging agents and selectively reduces the viability of BRCA1-mutated cancer cell lines. Together, 
our data provide a basis for the future development of CtIP-targeting compounds with the potential to treat 
patients with cancer.
INTRODUCTION
DNA double-strand breaks (DSBs) are the most cytotoxic lesions 
induced by ionizing radiation and certain chemotherapeutic agents. 
In contrast to normally dividing cells, hyperproliferating cancer 
cells are commonly exposed to higher loads of DSBs due to oncogene- 
induced replication stress and inherited or acquired defects in com-
ponents of the DNA damage response machinery (1). Consequently, 
efficient DSB repair is pivotal for cancer progression and frequently 
associated with therapy resistance (2). DSBs are mainly repaired by 
classical nonhomologous end joining (c-NHEJ) and homologous 
recombination (HR) in an error-free manner. Otherwise, DSBs with 
flanking homologous sequences can be subjected to mutagenic path-
ways, including alternative end joining (a-EJ) (3).
The human CtIP protein, in conjunction with the MRE11-
RAD50-NBS1 (MRN) nuclease complex, plays a critical role in DSB 
repair pathway choice through promoting DNA end resection, the 
initial step in HR (4). A-EJ, which is frequently found up-regulated 
in HR-deficient tumors associated with BRCA1 mutations, equally 
relies on CtIP-dependent end resection to expose microhomology 
regions used for annealing and repair of DSBs (5). Intriguingly, a 
study using mouse models of human breast cancer proposed that 
CtIP could promote tumorigenesis by facilitating a-EJ–dependent 
chromosomal instability (6). We have recently shown that CtIP protects 
nascent DNA at stalled replication forks from nucleolytic degradation 
by DNA2 (7). Moreover, we revealed that CtIP acts independently 
from BRCA1 in fork protection and that loss of CtIP in BRCA1- 
deficient cells aggravates replication stress–induced genomic instability, 
ultimately leading to increased cell death. On the basis of these findings, 
targeted inhibition of CtIP in BRCA1-mutated breast and ovarian 
cancers might represent a promising therapeutic approach (7).
Over the past decade, CtIP has emerged as a polyvalent adaptor 
protein containing several short linear sequence motifs implicated 
in protein-protein interactions. The overall sequence similarity be-
tween CtIP counterparts of different species is extremely poor, with 
the most conserved regions located at the N and C terminus. The 
N-terminal domain (NTD) harbors a coiled-coil region implicated 
in CtIP oligomerization (8–10); meanwhile, the C-terminal domain 
(CTD) facilitates DNA binding and MRN interaction (4, 11). A short, 
structurally defined -helical motif in the CtIP-NTD is required for 
proper tetramerization, conveying an architecture essential for 
effective DSB repair by HR. CtIP mutation L27E blocks tetramer-
ization and completely abrogates CtIP recruitment to DSB sites and 
HR (8). Overall, a DNA bridging mechanism was proposed, where-
by CtIP helps to link DNA ends, thereby positioning its CTD close 
to the breaks to promote DNA end resection by the MRN complex 
(12, 13). Accordingly, recombinant CtIP adopts a dumbbell-like struc-
ture, in which two globular DNA binding domains are held apart by 
a flexible “rod” corresponding to the coiled-coil domain of CtIP (14). 
Notably, Schizosaccharomyces pombe Ctp1 can form synaptic fila-
mentous complexes on double-stranded DNA (dsDNA) and bridg-
es dsDNA chains intra- or intermolecularly (15). Here, to establish 
proof of principle for therapeutic targeting of CtIP, we developed a 
cell-permeable constrained peptide inhibiting CtIP functions in genome 
maintenance by interfering with CtIP tetramer assembly.
RESULTS
Design of a hydrocarbon-stapled peptide mimicking 
and binding to the CtIP tetramerization motif
Tetramerization of CtIP is key to effective resection and homology- 
mediated repair of DSBs (8). Consequently, we sought to target CtIP’s 
“dimer-of-dimers” interface using an innovative peptide-based 
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approach. Precisely, we aimed to design a cell-permeable con-
strained peptide mimicking the -helical tetramerization motif. 
Hydrocarbon stapling constitutes the most successful and most 
widely used strategy to reinforce an -helical conformation (16). 
Two olefin-bearing non-natural amino acids are incorporated in 
place of nonessential residues and cross-linked using ruthenium- 
catalyzed ring-closing olefin metathesis (17). It is noteworthy that 
hydrocarbon stapling of peptides increases both their proteolytic 
stability and membrane penetrance (18, 19).
Multiple sequence alignment of the CtIP tetramerization motif 
(amino acids 18 to 31) among protein orthologs highlights an 
amphipathic two-turn helix with four highly conserved aromatic 
and hydrophobic residues (F20, L23, W24, and L27) packing against 
each other (Fig. 1A and fig. S1A) (8). To span these two helical turns 
and strengthen the bioactive -helical conformation, we chose to 
apply an all-hydrocarbon i,i+7 stapling system (Fig. 1B) (17). Exclusion 
of peptide residues important for helical folding pointed toward a 
promising staple position between D19 and K26 (Fig. 1B). In addition 
to a stapled peptide spanning the entire tetramerization domain 
(SP18–31), we synthesized a shortened 11-mer stapled peptide lacking 
the C-terminal “ECH” sequence (SP18–28) and its linear counterpart 
(LP18–28) (Fig. 1B). We speculated that spontaneous oxidation of C30 
could negatively affect peptide stability and conformation, while re-
moving E29 results in a more positively charged peptide with poten-
tially improved cellular uptake (20, 21).
To evaluate the structural impact of hydrocarbon stapling, we 
performed circular dichroism (CD) measurements of SP18–28 and 
LP18–28 and could report a drastic increase in -helical content upon 
stapling (Fig. 1C). Notably, the secondary structure in SP18–28 was 
profoundly heat stable, and no unfolding could be observed at tem-
peratures of up to 90°C (fig. S1B). To assess the ability of our pep-
tides to selectively bind the CtIP tetramerization motif, we purified 
recombinant CtIP-NTD18–145, folding into stable tetramers (8), and 
CtIP-NTD32–145, predominantly forming dimers (Fig. 1A and fig. S1C). 
Next, we measured binding affinities of fluorescein isothiocyanate 
(FITC)–labeled stapled peptides to CtIP-NTD18–145 using fluorescence 
polarization and observed a roughly 100-fold lower dissociation 
constant (Kd) value for SP18–28 (208.7 nM) as compared to SP18–31 
(Fig. 1D). Moreover, SP18–28 failed to bind CtIP-NTD32–145, indicat-
ing specific binding to the CtIP tetramerization motif (Fig. 1D).
SP18–28 induces higher-order aggregation of CtIP
We next subjected full-length recombinant CtIP proteins to native 
polyacrylamide gel electrophoresis (PAGE) and size exclusion chro-
matography coupled to multiple angle light scattering (SEC-MALS) 
analysis to determine CtIP oligomeric states upon incubation with 
the peptides. Under normal conditions, CtIP wild type (wt) and 
CtIP-L27E run as distinct single bands on native PAGE (Fig. 2A, 
lanes 2 and 10), and SEC-MALS shows that they adopt tetrameric 

















































































Fig. 1. A CtIP-mimetic stapled peptide adopts an -helical conformation and binds to the CtIP N terminus. (A) Top: Schematic drawing of full-length human CtIP 
(amino acids 1 to 897) harboring conserved NTDs and CTDs. The CtIP-NTD (amino acids 18 to 145) is divided into a tetramerization (Tet) motif (amino acids 18 to 31) and 
a coiled-coil region (amino acids 32 to 145) required for dimerization (Dim). Bottom: Multiple sequence alignments of the Tet motif in CtIP orthologs from Homo sapiens 
(hs), Mus musculus (mm), Xenopus laevis (xl), Danio rerio (dr), and S. pombe (sp). Conserved residues involved in  helix formation and required for tetramerization are 
highlighted in bold letters with blue boxes. (B) Design of hydrocarbon-stapled CtIP peptides. A staple was introduced by replacing D19 and K26 with olefin-bearing 
non-natural amino acids (R8 and S5) and subjecting the peptide to ruthenium-catalyzed ring-closing metathesis. In addition to a stapled peptide spanning the entire Tet 
motif (SP18–31), a shorter stapled version (SP18–28) and its linear counterpart (LP18–28) were synthesized. (C) CD spectra reveal enhanced  helicity for SP18–28 compared to 
LP18–28. (D) Fluorescence polarization binding curves of FITC-labeled SP18–28 and SP18–31 as a function of CtIP-NTD18–145 or CtIP-NTD32–145 concentration (mP, millipolariza-
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established (8, 14). Notably, CtIP tetramers run at anomalous positions 
relative to markers in both native PAGE and SEC (Fig. 2, A and B), 
most likely due to an estimated high content of intrinsic protein 
disorder that results in extended solution conformations in CtIP 
homologs (12). Incubation of CtIP-wt with LP18–28 caused no apparent 
structural changes (Fig. 2, A, lane 9, and B). Intriguingly, we ob-
served higher–molecular weight species of CtIP-wt forming in the 
presence of increasing amounts of SP18–28 (Fig. 2A, lanes 4 to 7). 
When the SP18–28 concentration was increased to ≥25 molar equiv-
alents, we noticed the formation of CtIP aggregates, manifesting as 
bands that do not enter the wells of native PAGE gels (Fig. 2A, lane 8) 
and visible precipitation of the CtIP sample. Accordingly, SEC-MALS–
based molecular mass calculation of the CtIP molecules remaining 
soluble after filtration tended toward larger protein complexes in 
the presence of excess SP18–28 (Fig. 2B). Moreover, the smaller 
CtIP tetramer peak combined with an additional peak running at 
the void volume further corroborated elevated CtIP protein multi-
merization in the presence of SP18–28 (Fig. 2B). Similarly, SEC-MALS 
analyses of recombinant CtIP-NTD18–145 incubated with a 10-fold 
molar excess of SP18–28 showed a trend toward higher–molecular mass 
species (fig. S2A). Furthermore, SDS-PAGE analysis of CtIP-NTD18–145 
products after cross-linking revealed that SP18–28 was able to induce 
the formation of high-order protein complexes in a concentration- -
dependent manner (Fig. 2C). SP18–28 did not hinder tetramerization- 
deficient CtIP-NTD18–145, L27E and CtIP-NTD32–145 proteins from 
forming dimers but largely compromised the tetrameric configura-
tion of CtIP-NTD18–145 (fig. S2B). Ctp1 in the fission yeast S. pombe 
has also been reported to feature an interlocking tetrameric helical 
dimer-of-dimers domain at its N terminus (12). In contrast to CtIP, 
however, we did not observe any major effects on Ctp1 structural 
integrity upon incubation with SP18–28 (fig. S3, A to C). Moreover, 
protein cross-linking experiments only revealed minor signs of Ctp1 
aggregation tetramerization at the highest amount of SP18–28 (fig. S3D). 
Together, these findings established that a CtIP-mimetic stapled 
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Fig. 2. SP18–28 engages CtIP tetamers to form aggregates. (A) Recombinant full-length CtIP-wt was supplemented with increasing concentrations of SP18–28 (1-, 2-, 4-, 
8-, 16-, and 32-fold molar excess) or LP18–28 (32-fold molar excess) and incubated for 30 min at RT before protein species were analyzed using blue native gel electropho-
resis. In addition, blue native gel analysis of mock-treated (no peptide, n.p.) CtIP-wt and L27E are shown. Disappearance of CtIP tetramers was quantified by normalizing 
band intensities in each lane to n.p. (B) SEC-MALS analyses of CtIP-wt, CtIP-L27E, and of CtIP-wt following incubation with 2- and 25-fold molar excess of SP18–28 and 
LP18–28 are illustrated. Horizontal dashed lines depict the expected molecular weights (MW) for monomeric, dimeric, and tetrameric CtIP species. Dotted lines show the 
values for the fitted molecular masses. Calculated MW (kilodalton) of reactions are indicated in parentheses in the graph legend. When SP18–28 concentration was in-
creased to 25 molar equivalents, extensive aggregation of CtIP-wt occurred as visible precipitation and is indicated by decreased UV absorption [A; arbitrary units (a.u.)]. 
(C) CtIP-NTD18–145 was either mock-treated (n.p.) or incubated with a 10-, 20-, or 50-fold molar excess of LP18–28 or SP18–28 for 30 min at RT. Thirty minutes after cross-linking, 
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CtIP-mimetic stapled peptides translocate to  
the nuclear compartment
Hydrocarbon stapling was previously shown to enhance cell penetra-
tion of peptides via endocytosis (19, 22). Moreover, the staple intro-
duced in our CtIP peptide is located at the amphipathic boundary, 
which has been previously found favorable for cellular uptake (18). 
Using live-cell confocal fluorescence microscopy, we observed effi-
cient intracellular delivery of FITC-labeled SP18–28 into HeLa and 
U2OS cell lines, whereas LP18–28 did not cross the cell membrane 
barrier (Fig. 3A). The punctuate, predominantly cytoplasmic stain-
ing pattern suggested endocytosis as the primary uptake route with 
moderate nuclear staining (Fig. 3A). To verify whether SP18–28 was 
able to reach the nucleus, we preextracted HeLa and U2OS cells 
before image acquisition to remove the cytoplasmic compartment. 
We could detect homogenous nuclear SP18–28 staining in both cell lines 
(Fig. 3B). Next, we monitored FITC intensity in peptide-transduced 
HeLa cells over a time course of 3 days using flow cytometry to deter-
mine uptake efficiency and the intracellular residence time. SP18–28 
was efficiently taken up during the first 24 hours with only a mod-
erate increase in FITC intensity occurring during the following days 
(Fig. 3C). In contrast, we could not detect substantial amounts of 
intracellular LP18–28 (Fig. 3C). Moreover, we observed much lower 
FITC signals with SP18–31 compared to SP18–28 despite identical staple 
placement, indicating superior uptake or stability of the shorter 
peptide (fig. S4, A and B). Collectively, our findings suggested that 
stapling rendered the CtIP peptide membrane permeable with adequate 
SP18–28 levels reaching the nuclear compartment.
SP18–28 impairs CtIP localization to DSBs and its ability 
to initiate DNA end resection
CtIP tetramerization was shown to be required for efficient CtIP 
accumulation at laser-induced DNA damage sites and, consequently, 
DNA end resection (8). To investigate the phenotypic impact of 
SP18–28 on CtIP nuclear distribution and DSB resection, we generated 
stable U2OS clones inducibly expressing siCtIP-resistant green fluo-
rescent protein (GFP)–tagged CtIP-wt or CtIP-L27E. As expected, 
Fig. 3. Hydrocarbon stapling mediates efficient intracellular delivery of SP18–28. (A) HeLa and U2OS cells were incubated with n.p. or 10 M FITC-labeled peptides for 
24 hours before staining with Hoechst 33342 and live-cell imaging using a confocal microscope. (B) HeLa and U2OS cells were incubated with 10 M FITC-labeled peptides 
for 24 hours. Afterward, cells were thoroughly washed and preextracted before fixation and DAPI staining. Cells were imaged using a wide-field microscope. Scale bars, 50 
and 10 m (zoom). (C) HeLa cells were incubated with 10 M FITC-labeled peptides for 24, 48, and 72 hours. Cells were harvested by trypsinization, and FITC signal was 
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CtIP-wt readily localized to microlaser-induced DSB tracks, where-
as CtIP-L27E failed to do so (Fig. 4A). SP18–28 treatment severely 
impaired CtIP recruitment to H2AX-decorated laser stripes, while 
LP18–28 had no significant effect (Fig. 4A). Following treatment with 
SP18–28, we frequently observed the formation of distinct nuclear 
GFP-containing focal structures, indicative of CtIP aggregation that 
is independent of DNA damage (Fig. 4B and fig. S5A). Notably, 
SP18–28 incubation failed to induce GFP-CtIP foci in cells expressing 
a CtIP mutant lacking the tetramerization motif (Fig. 4B and fig. S5A). 
In addition, endogenous CtIP was also prone to accumulate in focal 
structures upon SP18–28 treatment (fig. S5B). These findings suggested 
that cellular treatment with SP18–28 promotes the aggregation of CtIP 
tetramers, further corroborating our in vitro data. To examine 
whether these nonfunctional CtIP aggregates are more prone to 
being cleared by protein degradation, we performed Western blot 
analysis of time-course lysates from SP18–28-treated cells. However, 
we only observed a minor impact on steady-state levels of CtIP in a 
cycloheximide (CHX) chase experiment (fig. S5, C and D).
DNA end resection generates 3’ single-stranded DNA tails that 
are immediately coated by replication protein A (RPA) and subse-
quently replaced by RAD51 to form recombinogenic nucleopro-
tein filaments (3, 4). To study the impact of SP18–28 on DNA end 
resection, we quantified RPA accumulation at H2AX-decorated laser 
tracks. Intriguingly, upon treatment with SP18–28, U2OS cells dis-
played a pronounced decrease in RPA-positive stripes that was 
comparable to that observed in CtIP-depleted cells (Fig. 4C). As DNA 
end resection predominantly occurs during the S and G2 phases of 
the cell cycle (23), it was important to demonstrate that SP18–28 
treatment neither interferes with bulk DNA replication nor causes 
any significant changes in cell cycle distribution and cell prolifera-
tion (fig. S5, E and F). From these analyses, we concluded that incu-
bation of cells with SP18–28 compromised CtIP accumulation and 
resection at DSB sites, most likely due to the induction of dysfunc-
tional higher-order CtIP complexes.
SP18–28 interferes with homology-directed repair 
and replication fork protection
CtIP-mediated resection promotes error-free repair of DSBs by HR 
but, under certain conditions, also facilitates mutagenic repair by 
a-EJ implicated in tumorigenesis (5, 6). To evaluate the effect of 
SP18–28 on HR and a-EJ, we took advantage of two established DSB 
reporter cell lines (10, 24). We first analyzed HR efficiency of I-SceI–
induced DSBs in U2OS cells following incubation with CtIP-mimetic 
peptides and observed a nearly threefold decrease in HR frequency 
in the presence of SP18–28 that was comparable to CtIP depletion, 
while LP18–28 had no measurable impact (Fig. 5A). Moreover, SP18–28 
treatment caused a significant reduction in a-EJ frequency (Fig. 5B), 
reminiscent of what has been reported for tetramerization- and 
dimerization-deficient CtIP mutants (8, 10).
Besides its well-established role in the processing of DSB ends 
together with MRN, CtIP was recently reported to protect stalled 
replication forks from DNA2-dependent nucleolytic degradation 
(7). To first assess whether CtIP tetramerization itself is required for 
fork protection in response to DNA replication stress, we first per-
formed dual-labeling DNA fiber assays in U2OSGFP-CtIP-wt and 
U2OSGFP-CtIP-L27E cells treated with hydroxyurea (HU) to induce 
fork stalling (fig. S6). Consistent with a crucial function of CtIP 
tetramers in stabilizing stalled replication forks, we found that ex-
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Fig. 4. SP18–28-induced CtIP aggregates are defective in DNA end resection. (A) U2OS 
cells inducibly expressing siRNA-resistant GFP-CtIP-wt (U2OSGFP-CtIP-wt) or GFP-
CtIP-L27E (U2OSGFP-CtIP-L27E) were transfected with siCtIP to deplete endogenous 
CtIP. The next day, cells were grown in the presence or absence of indicated pep-
tides (10 M), Dox, and BrdU for 24 hours before microirradiation. Cells were fixed 
30 min after laser beam irradiation and immunostained for H2AX before DNA 
staining with DAPI and fluorescence microscopy. Left: Representative images. 
Scale bar, 10 m. Right: Graph depicts percentages of GFP-positive laser tracks relative 
to the total of H2AX-positive stripes. Data, means ± SEM (n = 4). (B) U2OSGFP-CtIP-wt 
and U2OSGFP-CtIP-1–31 cells, inducibly expressing an N-terminally truncated CtIP variant 
lacking the tetramerization motif, were transfected with siCtIP to deplete endoge-
nous CtIP. The next day, cells were grown in the presence of the indicated peptides 
(10 M) and Dox for 24 hours. Cells were fixed, stained with DAPI, and imaged us-
ing a fluorescence microscope. Left: Representative microscopy images. Scale bar, 
10 m. Right: Graph shows percentage of cells with more than five GFP-CtIP foci. 
Data are presented as means ± SEM (n = 4). At least 250 cells were scored for each 
condition. (C) Parental U2OS were transfected with control (CNTL) or CtIP siRNA 
oligos for 48 hours. Alternatively, cells were treated with 10 M of indicated pep-
tides for 24 hours before microirradiation. Cells were grown for 24 hours in BrdU 
and, 30 min after irradiation, fixed and coimmunostained for RPA and H2AX. DAPI 
was used to stain the DNA. Left: Representative microscopy images. Scale bar, 10 m. 
Right: Graph illustrates the percentage of RPA-positive relative to H2AX-positive 
laser tracks. Data, means ± SEM (n = 3). Statistical significance in (A) and (C) was 
calculated with Tukey’s multiple comparison test using one-way ANOVA. Statistical 
significance in (B) was calculated with Sidak’s multiple comparison test using two-
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in CtIP-depleted cells (fig. S6). We found that SP18–28 treatment 
promotes extensive fork degradation in U2OS cells, comparable to 
that observed upon CtIP depletion (Fig. 5C). SP18–28 treatment of 
U2OSGFP-CtIP-L27E cells did not result in any additive increase in fork 
degradation (fig. S6), indicating that SP18–28 mediates its cellular 
activity largely through selective CtIP inhibition. Collectively, these 
findings further substantiate the use of SP18–28 as a potent and specific 
inhibitor of CtIP tetramerization and, consequently, of homology- 
directed DSB repair and fork protection.
SP18–28 confers DNA damage hypersensitivity and selectively 
kills BRCA1-mutated cancer cells
Given that unrepaired DSBs are highly cytotoxic, CtIP-depleted cells 
are hypersensitive to various DNA-damaging agents, most promi-
nently to drugs inducing replication-associated DSBs, such as DNA 
interstrand–cross-linking drugs, DNA topoisomerase poisons [e.g., 
camptothecin (CPT)], and PARP1 inhibitors (e.g., olaparib) (4, 25–27). 
Therefore, we next sought to examine the peptide’s potency to 
enhance cell death following treatment with anticancer drugs using 
clonogenic survival assays. Continuous exposure of HeLa cells to 5 M 
SP18–28 considerably reduced colony formation when combined with 
increasing concentrations of either CPT or olaparib (Fig. 6, A and B). 
To more precisely determine the dose-dependent effects of acute 
versus chronic peptide treatment on DNA damage sensitivity, we 
performed clonogenic assays with HeLa cells grown in the absence 
or presence of olaparib (fig. S7A). While an acute (24-hour) treatment 
with 10 M SP18–28 is well tolerated and resulted in significant olaparib 
hypersensitivity, a prolonged chronic treatment with the same dose 
caused extreme cytotoxicity on its own (fig. S7A). Consistent with 
data obtained from HeLa cells (Fig. 6A), chronic treatment with 5 M 
SP18–28 significantly resensitized CtIP-wt– but not CtIP-L27E– 
expressing U2OS cells to CPT, indicating that peptide-mediated 
chemosensitization can be mainly attributed to the lack of functional 
CtIP tetramers (fig. S7B).
We have previously reported that combined deficiency of CtIP 
and BRCA1 synergistically compromises fork stability and provokes 
elevated levels of chromosomal instability in the absence of exogenous 
DNA damage (7). Furthermore, CtIP depletion drastically reduced 
the viability of a panel of BRCA1 mutant breast cancer cell lines, 
implying a synthetic sick genetic interaction between these two factors 
(7). Thus, we speculated that SP18–28 treatment may be particularly 
toxic for BRCA1-deficient cells. SP18–28 incubation resulted in reduced 
clonogenic survival of MDA-MB-436 and SUM149PT BRCA1 
mutant breast cancer cell lines but not of BRCA1-proficient MCF7 
breast cancer or MCF10A and RPE1 nontumorigenic cell lines 
(Fig. 6C). To exclude potential off-target effects of SP18–28 in induc-
ing synthetic lethality in BRCA1-deficient cells, we used an isogenic 
MDA-MB-436 cell line pair (28) and observed decreased viability 
exclusively in control but not in BRCA1 “add-back” cells following 
acute treatment with 10 M SP18–28 (fig. S7C). Moreover, in response 
to CPT treatment, we noticed a considerable reduction in the phos-
phorylation levels of RPA2 and CHK1 specifically in SP18–28-treated 
MDA-MB-436 control cells (fig. S7D), indicative of impaired DSB 
resection (4). Overall, these findings support a scenario in which 
targeted CtIP inhibition is incompatible with viability when applied 
to BRCA1-deficient cells, likely due to severe combined deficiencies 
in DSB repair and fork protection.
DISCUSSION
Cancer cells strongly rely on efficient mechanisms sensing and re-
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Fig. 5. SP18–28 treatment compromises DSB repair and replication fork stability. (A) Forty-eight hours after siRNA transfection, U2OS EGFP-HR were transfected with 
I-SceI expression plasmid. Alternatively, cells were incubated with depicted peptides (10 M) 4 hours after I-SceI transfection for 24 hours. Cells were harvested 48 hours 
after I-SceI transfection, and the percentage of GFP-positive cells was determined by flow cytometry. A minimum of 20,000 events were recorded. The graph depicts the 
percentages of GFP-positive cells as a readout for HR frequency. (B) U2OS EGFP-aEJ reporter cell line was transfected with I-SceI 6 hours after siRNA transfection. The next 
day, cells were treated with 10 M LP18–28 or SP18–28 for 24 hours before harvesting the cells 72 hours after I-SceI transfection and subjecting them to flow cytometry. A 
minimum of 20,000 events were recorded. The percentage of GFP-positive cells was used as a readout for the frequency of a-EJ. Data in (A) and (B) are represented as 
means ± SEM (n = 4). Statistical significance was calculated with unpaired two-tailed t test (****P ≤ 0.0001; ***P ≤ 0.001; **P ≤ 0.01; *P ≤ 0.05). (C) U2OS cells were transfected 
with indicated siRNA oligos for 48 hours. Alternatively, cells were mock-treated (n.p.) or treated with 10 M of the indicated peptides for 24 hours before pulse-labeling 
with CIdU/IdU for 30 min each and HU treatment (2 mM, 4 hours). Left: Schematic of labeling protocol to evaluate fork degradation is shown. In addition, representative 
images of CldU and IdU replication tracks are depicted. Right: Data are represented as scatterplot of IdU/CldU tract length ratios for individual replication forks. Numbers 
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CtIP-mediated DNA end resection is required for DSB repair by HR 
to resist conventional DNA-damaging anticancer regimens (2). We 
reasoned that targeted inhibition of CtIP’s resection activity may 
provide a suitable approach for enhancing the efficacy of radio- and 
chemotherapy and may also be applied as monotherapy in certain 
genetic contexts based on the concept of synthetic lethality. Recent 
findings have established that CtIP and Ctp1 tetramerization, which 
is mediated via a structurally defined short -helical motif in the 
N terminus, is crucial for its DNA bridging and repair function 
(8, 12, 14, 15).
Here, we developed a peptide-based CtIP inhibitor targeting its 
tetramerization domain. Specifically, we reinforced an -helical 
two-dimensional conformation by a constraining technique, re-
ferred to as hydrocarbon peptide stapling (29, 30). We found that a 
peptide spanning CtIP residues 18 to 28 with an i,i+7 staple at loca-
tions 19 and 26 (SP18–28) was the best CtIP binder and interfered with 
CtIP tetramerization. The cell-permeable SP18–28 inhibited CtIP 
accumulation at DSB sites, causing defects in DNA end resection, 
HR, and fork protection and conferring hypersensitivity to DNA- 
damaging drugs. Most relevant from a clinical point of view, we 
observed SP18–28-mediated killing of BRCA1-mutated breast cancer 
cells, whereas no apparent toxicity was detected in nontumorigenic 
cell lines.
CtIP assembles as a dumbbell-like structure, whereby two C-terminal 
DNA binding domains are held apart by two coiled-coil domains (14). 
Intriguingly, the L27E point mutation not only impairs the dimer- 
of-dimers arrangement but also heavily reduces DNA binding (14). 
Consequently, targeting tetramerization may cause severe alterations 
in CtIP function. Biochemical evidence suggests that the tetramer 
seems to be the constitutive oligomeric state of CtIP (13). On the 
basis of our in vitro experiments, SP18–28 specifically binds the CtIP 
tetramerization domain, but instead of disrupting the tetramers into 
its dimeric or monomeric counterparts, the stapled peptide promotes 
extensive CtIP aggregation. Sae2, the yeast counterpart of CtIP, forms 
an inactive soluble multimeric complex during G1 phase and transi-
tions to active oligomers upon extensive phosphorylation in S-G2 (31). 
Similarly, SP18–28 seems to trap CtIP in an inactive multimeric protein 
complex by an as-yet unknown mechanism. SP18–28 neither bound 
the N-terminal coiled-coil domain nor aggregated tetramerization- 
deficient mutants CtIP-NTD18–145,L27E or CtIP-NTD32–145. Thus, we 
hypothesize that the CtIP-mimetic peptides can stably associate with 
the CtIP tetramerization motif and induce the formation of complex 
CtIP-peptide hetero-oligomers.
Several studies have shown that CtIP/Ctp1 promotes inter- and 
intramolecular DNA bridging (12, 14, 15). Notably, Andres and 
colleagues (15) reported that Ctp1-mediated DNA bridging relies 
on the formation of synaptic filaments involving, on average, 12 Ctp1 
tetramers. These findings suggest that dynamic oligomerization states 
of Sae2/Ctp1 are critical for efficient DSB repair. However, no 
reports about the dynamic control of CtIP oligomerization in a 
biological context are available. It is conceivable that CtIP may be 
able to transit between different oligomeric conformations through 
distinct post-translational modifications or DNA binding as it was 
reported for Sae2/Ctp1 (12, 31, 32). Overall, our findings suggest 
A
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Fig. 6. SP18–28 confers hypersensitivity to DNA-damaging agents and is toxic to BRCA1-mutated breast cancer cell lines. (A) HeLa cells were transfected with the 
indicated siRNAs or left untransfected for peptide treatment. Twenty-four hours later, cells were plated at low cell density into 24-well plates. Another 24 hours later, 
non-siRNA transfected cells were either mock-treated (n.p.) or treated with 5 M SP18–28 together with increasing CPT concentrations and grown for 10 days. Top: Repre-
sentative images of a colony formation assay are shown. Bottom: Clonogenic survival was determined by quantifying the colony intensity of CPT-treated relative to un-
treated cells. Data are presented as means ± SEM (n = 4). (B) The same cells as in (A) were treated with indicated olaparib concentrations with or without 5 M SP18–28. Cells 
were grown for 10 days before fixation and staining with crystal violet. Top: Representative images of survival assay are depicted. Bottom: Clonogenic survival was deter-
mined by quantifying the colony intensity of olaparib-treated relative to untreated cells. Data are presented as means ± SEM (n = 5). (C) MDA-MB-436, SUM149PT, MCF7, 
MCF10a, and RPE1-hTERT were seeded at low cell density into 24-well plates and grown in the absence (n.p.) or presence of 10 M LP18–28 or SP18–28 for 24 hours. After 
10 days, cells were fixed, and colony intensities were measured. Top: Representative images of colony formation. Bottom: Graph illustrates survival by calculating the 
colony intensity of peptide-treated relative to mock-treated (n.p.) cells. Data are presented as means ± SEM. Statistical significance was calculated with Sidak’s multiple 
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that CtIP can adopt distinct conformational states, such as inactive 
higher-order multimers, to regulate DSB repair.
Hydrocarbon stapling frequently increases membrane penetrance, 
whereas native peptides commonly do not cross the cell membrane 
barrier (33). By hiding the hydrophilic peptide backbone and pre-
senting the hydrophobic residues on one side, stapling may alleviate 
membrane crossing (22). Penetration mostly occurs through endo-
cytosis, which conforms with our observation of intracellular punc-
tuate staining patterns upon incubation with FITC-labeled SP18–28 
(22, 34). This uptake mode is significantly slower than direct trans-
duction through the membrane, which is frequently observed with 
cell-penetrating peptides, and requires time to escape from endosomes 
(34). Although a major part seemed to be trapped in endosomes, a 
significant fraction of SP18–28 reached the nucleus and was sufficient 
to trigger a biological response. We speculate that the overall positive 
net charge of SP18–28 combined with an extended hydrophobic in-
terface conferred the peptide a higher intracellular uptake rate than 
its longer counterpart SP18–31 (18).
Tetramerization-deficient CtIP mutants are defective in DNA 
end resection and homology-directed repair of DSBs most likely 
due to impaired dynamic CtIP redistribution at broken chromatin 
(8). Likewise, we observed a drastic decrease in CtIP redistribution 
to laser-induced DSBs and homology-mediated repair upon treatment 
with SP18–28. These findings were most likely related to the formation 
of higher-order CtIP oligomers with abrogated spatial redistribution 
to DSB sites. CtIP-L27E mutant is proficient in binding to MRN 
and undergoes phosphorylation despite its inability to accumulate 
at breaks (8, 35).
Last, we report that inhibition of CtIP tetramerization interferes 
with its recently established role in the protection of reversed forks 
(7). The observed synergism between CtIP and BRCA1 in alleviat-
ing replication stress–induced chromosomal instability could be 
exploited by treating BRCA1-mutated cells with the CtIP inhibitor 
SP18–28 (7). We observed specific cell killing in a BRCA1-deficient 
background, whereas we did not perceive a negative impact on cell 
survival of BRCA1 wt cell lines MCF7, MCF10A, and RPE1. Whether 
the lack of toxicity in MCF10A and RPE1 cells can solely be attributed 
to the presence of BRCA1 or whether it can also be partially explained 
by an overall decreased cellular uptake rate in normal versus cancer 
cells requires further investigation (36).
SP18–28 seems to be a potent inhibitor of functional CtIP oligom-
erization with a relatively low dissociation constant in the nanomolar 
range. Nevertheless, we had to provide peptide concentrations of 
5 M or higher to observe bioactivity. A major limitation of the 
stapled peptide is its predominant endocytic uptake resulting in 
high peptide amounts being trapped in endosomes. To transform 
this first-generation compound into a lead compound, diversification 
of staple type and position combined with fine-tuning core hydro-
phobicity and positive net charge is likely to increase cellular uptake 
and robust bioactivity (37, 38). Prominent amino acid substitutions 
include the incorporation of arginines or arginine derivatives, namely 
homo-arginine and 4-guanidino-phenylalanine (38). Alternatively, 
complementary drug delivery strategies including the use of cell- 
penetrating peptides and nuclear localization signals could be used 
to improve cytoplasmic and nuclear uptake efficiencies (36, 38).
Overall, SP18–28 constitutes a potent peptide therapeutic whose 
bioactive concentration range is comparable to successful peptido-
mimetics, including various p53/MDM2-targeting stapled peptides 
and a proapoptotic BH3-mimetic peptide (19, 21). Intriguingly, 
clinical trials of ALRN-6924, a stapled peptide reactivating p53 ex-
pression, are underway and propose promising future applications 
of constrained peptides in the clinic (39). Notably, a recent report 
suggested that the extended drug interface of peptide therapeutics 
entails a higher resilience to point mutations in the target protein 
and impedes the acquisition of drug resistance (40).
We speculate that the stapled CtIP peptide inhibitor could have 
diverse areas of application in cancer therapy. In addition to conferring 
increased sensitivity to conventional DNA-damaging agents, CtIP- 
targeting therapeutics could be used in combination with PARPi in 
HR-proficient tumors. HR-mediated repair of DSBs predominantly 
operates during S phase of the cell cycle and is thus more significant 
for rapidly dividing cancer cells than for neighboring, healthy cells, 
providing a broad therapeutic window. Inhibition of mutagenic DSB 
repair by a-EJ may prolong the response of HR-deficient tumors to 
PARPi by preventing resistance acquisition (41). In addition to HR 
reactivation, restoration of fork protection seems to be a major 
mechanism conferring PARPi- and chemoresistance (42, 43). Con-
sequently, administration of SP18–28 would allow a two-pronged 
strategy for treating PARPi-resistant cancers by simultaneous dis-
ruption of HR and fork protection. Last, we provide evidence that 
SP18–28 can be applied in BRCA1-deficient tumors and is not toxic 
to noncancerous cell lines, which would allow selective tumor killing.
MATERIALS AND METHODS
Bacterial strains
CtIP-NTD18–145 and CtIP-NTD32–145 were expressed in electrocom-
petent BL21-CodonPlus-RIL Escherichia coli. XL1-blue competent 
E. coli cells were used for plasmid cloning.
Cell culture
Human embryonic kidney 293 T, HeLa, U2OS, RPE1-hTERT [American 
Type Culture Collection (ATCC)], MCF7, U2OS EGFP-HR, and 
U2OS EGFP-aEJ cells were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) (Gibco, Thermo Fisher Scientific) supplemented 
with 10% fetal calf serum (FCS; Gibco, Thermo Fisher Scientific), 
penicillin (100 U/ml), and streptomycin (100 g/ml) (1% P/S; Gibco, 
Thermo Fisher Scientific). U2OSGFP-CtIP-wt, U2OSGFP-CtIP-L27E, and 
U2OSGFP-CtIP-1–31 cells were grown in DMEM containing 10% Tet 
system–approved FCS (Gibco, Thermo Fisher Scientific) and 1% P/S. 
GFP-CtIP expression was induced by providing doxycycline (Dox; 
1 g/ml; TaKaRa Clontech) for 24 hours. MDA-MB-436 (ATCC), 
MDA-MB-436 pLenti-IRES-GFP-BFP, and MDA-MB-436 pLenti-
IRES-BFP-HABRCA1 (28) were cultured in RPMI 1640 medium 
(Gibco, Thermo Fisher Scientific) supplemented with 10% FCS, 2 mM 
l-glutamine, and 1% P/S. SUM149PT (BIOIVT) cells were maintained 
in HAM’s F12 medium (Gibco, Thermo Fisher Scientific) containing 
10% FCS, 2 mM l-glutamine, and 1% P/S. MCF10A (ATCC) cells 
were cultured in DMEM/F12 (Gibco, Thermo Fisher Scientific) 
supplemented with 5% horse serum (Gibco, Thermo Fisher Scien-
tific), human epidermal growth factor (20 ng/ml; Sigma-Aldrich), 
hydrocortisone (0.5 g/ml; Sigma-Aldrich), insulin (10 g/ml), and 
1% P/S. All cell lines were grown at 37°C in an atmosphere contain-
ing 6% CO2.
Peptides
Custom-designed peptides were purchased from Bachem AG (Bubendorf, 
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N-terminal acetylation and C-terminal amidation. Alternatively, 
peptides were labeled with a fluorescein (FITC) tag at the N terminus. 
A comprehensive list with the exact peptide sequences can be found 
in table S1. Lyophilized LP18–28, SP18–28, and FITC-LP18–28 were dis-
solved in ddH2O at 1 mg/ml, whereas 1 mg/ml of FITC-SP18–28 and 
FITC-SP18–31 was solubilized in 50% dimethyl sulfoxide.
siRNA and antibodies
Small interfering RNA (siRNA) sequences are listed in table S2. 
Transfections were performed with a final concentration of 10 nM 
using Lipofectamine RNAiMAX (Thermo Fisher Scientific) accord-
ing to the manufacturer’s instructions. A detailed list of primary 
and secondary antibodies is provided in table S3.
Recombinant protein expression and purification
CtIP-L27E mutation was introduced by site-directed mutagenesis 
of 3xFLAG-CtIP-wt expression vector (8) using primers listed in 
table S2. The CtIP-NTD ranging from amino acids 18 to 145 was 
polymerase chain reaction (PCR)–amplified from FLAG-CtIP-wt 
and L27E plasmids (primers, see table S2) and ligated into pET28 
MBP-TEV vector (Addgene, #69929) upon restriction digest with 
Bam HI and Xho I (NEB). CtIP-NTD32–145 was generated by PCR of 
pET28-MBP TEV CtIP-NTD18–145 using 5′ phosphorylated primer 
“CtIP-NTD32–145 for” and “CtIP-NTD32–145 rev” (see table S2 for 
sequences) and subsequent plasmid religation.
CtIP-NTD fragments were purified as described previously (11). 
Briefly, constructs were expressed in E. coli BL21-CodonPlus-RIL for 
20 hours at 18°C using 0.5 mM isopropyl--d-thiogalactopyranoside. 
Pellets were resuspended in lysis buffer [50 mM tris (pH 8.0) and 
300 mM NaCl], snap-frozen, and thawed on ice. Subsequently, 
1 mM phenylmethylsulfonyl fluoride, protease inhibitor cocktail 
(Roche), and lysozyme (0.1 mg/ml; Sigma-Aldrich) were added be-
fore stirring the bacterial lysates for 15 min at 4°C and sonicating 
them for 5 min. Insoluble material was removed by ultracentrifuga-
tion at 125,000g for 1 hour, and supernatant was loaded onto amy-
lose affinity columns (5-ml MBPTrap HP, GE Healthcare). Fusion 
protein was eluted with 20 mM tris (pH 8.0), 2 mM -mercaptoethanol 
(-me), 300 mM NaCl, and 2 M methyl -d-glucopyranoside (AMG; 
Sigma-Aldrich), and a buffer exchange into 20 mM tris (pH 8.0), 
300 mM NaCl, and 5 mM -me was performed using a HiPrep 26/10 
Desalting column (GE Healthcare). N-terminal His6-MBP tag was 
removed by overnight cleavage at 20°C using MBP-tagged TEV 
protease (Gene and Cell Technologies) in a ratio of 1:5. TEV protease 
cleavage site products were captured by amylose affinity chroma-
tography (5-ml MBPTrap HP, GE Healthcare). Further contaminants 
were removed by preparative SEC (HiLoad 16/600 Superdex 75, GE 
Healthcare) in 20 mM tris (pH 8.0), 150 mM NaCl, and 5 mM -me. 
Full-length CtIP was purified according to (14). Full-length Ctp11–294 
and MBP-tagged Ctp11–60 proteins were expressed and purified as 
described previously (12).
Fluorescence polarization
CtIP-NTD18–145 or CtIP-NTD32–145 was serially diluted in black, 
flat-bottom 96-well plates (Greiner) in 20 mM tris (pH 8.0) and 150 mM 
NaCl. FITC-SP18–28/18–31 stock (1 mg/ml) was diluted at 1:10,000, 
and 50 l of protein dilutions was mixed with 50 l of FITC-labeled 
peptides before incubating for 10 min at room temperature (RT). 
Fluorescence polarization was recorded with an excitation wavelength 
of 470 nm, emission wavelength of 527 nm, 20-nm emission band-
width, and 100 reads per well using a Tecan Safire 2 spectrometer. Kd 
values were calculated by nonlinear regression of dose-response curves.
CD spectroscopy
CD spectroscopy data were collected on a Jasco J-710 spectropolarim-
eter. A total of 0.2 or 0.05 mg/ml of LP18–28 or SP18–28 in ddH2O was 
measured with a 1-mm path length cuvette. CD spectra were recorded 
at 0.5-nm intervals between 190 and 260 nm at 25°C. CD thermal 
denaturation data were recorded at 210 nm at 0.2°C intervals start-
ing at 25° until 90°C.
Blue native PAGE
Reactions were assembled in a volume of 10 l with a 1.5 M final 
concentration of CtIP and either 0, 1.5, 3, 6, 12, 24, or 48 M LP/
SP18–28 in buffer A [10 mM tris (pH 8.0), 25 mM NaCl, 5% glycerol, 
and 0.5 mM dithiothreitol (DTT)] and 1× Blue Native Loading buffer 
[50 mM bis-tris (pH 7.2), 6 N HCl, 50 mM NaCl, 10% (w/v) glycerol, 
and 0.001% Ponceau S]. After incubation for 30 min at RT, samples 
were loaded onto a NativePAGE Novex 3 to 12% bis-tris gel (Invitrogen) 
and run at 150 V for 75 min. Gels were fixed in 40% methanol (MeOH) 
and 10% acetic acid and destained with 8% acetic acid.
Ctp1 (1.5 M) was incubated with SP18–28 for 30 min at RT in 10 mM 
tris (pH 8), 25 mM NaCl, 0.5 mM DTT, and 10% glycerol. Thereafter, 
10 l of each reaction was loaded onto NuPAGE 4 to 12% bis-tris 
gels (Invitrogen) that were then run at 150 V for 6 hours in 50 mM 
Mops and 50 mM tris base (pH 7.7) running buffer.
Size exclusion chromatography coupled to multiple angle 
light scattering
SEC-MALS was used to determine the absolute molecular mass of 
full-length CtIP in the presence and absence of LP18–28 and SP18–28. 
Reactions were assembled in a total volume of 100 l with a 10 M 
final concentration of CtIP and either 0, 20, or 250 M peptides in 
buffer A [12 mM tris-HCl (pH 8.0), 150 mM NaCl, 6% glycerol, and 
0.6 mM DTT]. These were incubated on ice for 1 hour and then at RT for 
30 min before being loaded at 0.5 ml/min onto a Superose 6 10/300 
SEC column (GE Healthcare) in 20 mM tris (pH 8.0), 200 mM NaCl, 
and 0.5 mM Tris (2-Carboxyethyl)-Phosphin (TCEP) using an Agilent 
high-performance liquid chromatography (HPLC). The eluate from 
the column was coupled to a DAWN HELEOS II MALS detector 
(Wyatt Technology) and an Optilab T-rEX differential refractometer 
(Wyatt Technology). ASTRA 6 software (Wyatt Technology) was used 
to collect and analyze light scattering and differential refractive in-
dex data according to the manufacturer’s instructions. Molecular masses 
and estimated errors were calculated across individual eluted peaks.
An Agilent 1100 HPLC was used to inject 100 l of CtIP NTD18–145 
(2 mg/ml), CtIP NTD18–145 L27E (2 mg/ml), and CtIP NTD32–145 
(8 mg/ml) individually onto a WTC-030S5 size exclusion column 
(Wyatt Technology) with a 1 ml/min flow rate in running buffer [20 mM 
tris (pH 8), 150 mM NaCl, and 2 mM -me running buffer]. CtIP 
NTD18–145 (20 M) was incubated with 200 M SP18–28 for 30 min 
on ice and then centrifuged for 10 min at high speed to remove 
excess aggregates before injection of 100 l. The eluate from the 
column was coupled to a DAWN MALS detector (Wyatt Tech-
nology) and an Optilab RI detector (Wyatt Technology). ASTRA 7 
software (Wyatt Technology) was used to collect and analyze light 
scattering and differential refractive index data according to the 
manufacturer’s instructions. Molecular masses and estimated errors 
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SEC of Ctp1 proteins was performed on a Superdex S200 in-
crease 10/300 GL column (Cytiva) in 20 mM tris (pH 8), 150 mM 
NaCl, and 2 mM -me. A total of 32 M Ctp1 ± 5-fold excess of 
SP18–28 or 10 M MBP-Ctp11–60 ± 10-fold excess of SP18–28 was in-
cubated for 1 hour at 4°C before precipitation being spun down and 
100 l being injected onto the column.
Protein cross-linking
Recombinant proteins (1 or 2 g) were mixed with peptides in 1× 
phosphate-buffered saline (PBS) and incubated at RT for 30 min 
with gentle shaking. Chemical cross-linking was carried out with 
100 M disuccinimidyl suberate (Sigma-Aldrich) at RT for 30 min 
with gentle shaking. Cross-linking reactions were quenched by the 
addition of 50 mM tris (pH 7.5) for 5 min at RT before boiling in 1× 
SDS sample buffer [5 mM tris (pH 6.8), 10% glycerol, 1.6% SDS, 
100 mM DTT, and 0.02% bromophenol blue] for 5 min. Protein 
samples were separated by SDS-PAGE, and the gels were stained 
with InstantBlue (Expedeon).
Generation of U2OS GFP-CtIP Flp-In T-REx cells
Mammalian expression vector pcDNA5/FRT/TO-GFP-CtIP L27E 
was generated by site-directed mutagenesis of pcDNA5/FRT/TO-
GFP CtIP-wt using primers listed in table S2. Expression vector 
pcDNA5/FRT/TO-GFP-CtIP 1–31 was generated by PCR linear-
ization of pcDNA5/FRT/TO-GFP-CtIP-wt using 5′ phosphorylated 
primers “CtIP del1-31 for” and reverse primer “CtIP del rev” (table S2). 
Subsequently, plasmids were religated using T4 DNA ligase (NEB). 
U2OS cell lines stably expressing siRNA-resistant GFP-CtIP-wt, 
L27E, or 1–31 were generated using the Flp-In T-REx system as 
described previously (44). Precisely, U2OS Flp-In T-REx cells were 
transfected with pcDNA5/FRT/TO-GFP-CtIP constructs and Flp re-
combinase expression plasmid pOG44 (1:9 ratio) using Lipofectamine 
3000 transfection reagent (Invitrogen) according to the manufac-
turer’s instructions. Forty-eight hours after transfection, cells were 
plated at varying densities, and 6 hours later, cell selection was per-
formed by supplementing medium with hygromycin B (250 g/ml; 
InvivoGen) and blasticidin S (15 g/ml; InvivoGen) for 14 days. 
Single-cell clones were picked and analyzed for GFP expression by 
immunoblotting, flow cytometry, and immunofluorescence micros-
copy. To induce GFP-CtIP expression, cells were grown for 24 hours 
in Dox (1 g/ml).
Confocal and immunofluorescence microscopy
Cells were seeded into eight-well chamber imaging slides (Ibidi) 
and grown overnight. Upon treatment with 10 M FITC-labeled 
peptides for 24 hours, cells were imaged in Live Cell Imaging Medium 
(Gibco, Thermo Fisher Scientific) containing Hoechst 33342 (0.5 g/ml; 
Thermo Fisher Scientific) using CLSM SP5 Mid UV-VIS Leica with 
63× objective at 37°C and ambient CO2 concentrations. Nuclear 
peptide uptake was evaluated by washing cells twice with cold PBS 
before preextraction for 5 min on ice [25 mM Hepes (pH 7.4), 50 mM 
NaCl, 1 mM EDTA, 3 mM MgCl2, 300 mM sucrose, and 0.5% Triton 
X-100], fixation with 4% formaldehyde (w/v) in PBS for 15 min at 
RT, and imaging with Leica DM6, 63× objective.
Laser microirradiation was carried out as described previously 
(25). Briefly, cells were grown in 10 M 5-bromo-2′-deoxyuridine 
(BrdU) for 24 hours before irradiation. Laser microirradiation was 
performed using a MMI CELLCUT system containing an ultraviolet 
(UV) A laser of 355 nm. Energy output was set to 50%, and each cell 
was exposed to laser beam for <300 ms. Cells were released for 30 min 
before fixation in 4% formaldehyde (w/v) in PBS for 15 min and 
permeabilization with 0.5% Triton X-100 (w/v) in PBS for 5 min at 
RT. After blocking with 3% FCS (w/v) in PBS for 1 hour, cells were 
stained with primary antibodies (table S3) for 2 hours. Staining with 
secondary antibodies (table S3) was performed for 1 hour. Cov-
erslips were mounted with Vectashield supplemented with DAPI 
(4′,6-diamidino- 2-phenylindole; Vector Laboratories), and im-
ages were acquired on a Leica DM6, 63× objective. For CtIP foci 
analyses, cells were fixed in 4% formaldehyde (w/v) in PBS for 
15 min before permeabilization with 0.5% Triton X-100 (w/v) in 
PBS for 5 min at RT. A blocking step with 3% FCS (w/v) in PBS for 
1 hour was followed by primary (2-hour) and secondary (1-hour) 
staining at RT.
Immunoblotting
Cells were lysed in Laemmli buffer [4% SDS, 20% glycerol, and 120 mM 
tris (pH 6.8)], resolved by SDS-PAGE, and transferred to nitrocellulose 
membranes. Immunoblotting was performed with indicated primary 
antibodies (table S3) overnight at 4°C and horseradish peroxidase–
conjugated secondary antibodies (table S3) for 1 hour at RT. Pro-
teins were visualized using the Advansta Western Bright enhanced 
chemiluminesence reagent (Advansta) and Fusion Solo S imaging 
system. For the CHX chase assay, U2OS cells were either mock-treated 
or incubated with the indicated peptides for 24 hours and afterward 
treated with CHX (50 g/ml; Sigma-Aldrich) for 0, 2, or 6 hours 
before cell lysis.
Flow cytometry analysis
HeLa cells were seeded into six-well plates and incubated with peptides 
in a volume of 2 ml for varying time points. Cells were harvested by 
trypsinization, washed, and resuspended in PBS before subjecting 
them to flow cytometry analysis. FITC intensity was measured with 
an Attune Nxt flow cytometer equipped with a 488-nm laser and 
530/30 band-pass filter. Analysis of 5-Ethynyl-2′-deoxyuridine (EdU) 
incorporation was carried out using the Click-iT EdU technology 
(Thermo Fisher Scientific) as described in the manufacturer’s in-
structions. A minimum of 20,000 events were recorded.
Cell proliferation assay
A total of 125 and 250 U2OS cells were seeded in triplicates in 96-well 
plates in a volume of 90 l. Twenty-four hours after seeding, 10 l of 
medium only or medium with the indicated peptides was added to 
the wells reaching a final peptide concentration of 5 M. Cell prolifer-
ation was monitored using a CellTiter-Blue–based (Promega) approach 
at specific time points (0, 2, 5, and 7 days after peptide treatment). 
In brief, 20-l CellTiter-Blue reagent (Promega) was added to the 
wells, incubated for 4 hours, and fluorescence intensity was mea-
sured at 560/590 nm using a SpectraMax M5 microplate reader 
(Molecular Devices).
HR and a-EJ reporter assay
HR reporter assay was performed as described previously (45, 46). 
Briefly, U2OS EGFP-HR were seeded into a 12-well plate and the 
day after transfected with pCBA I-SceI expression plasmid using 
jetPRIME transfection reagent (Polyplus). Four hours later, medium 
was exchanged, and cells were incubated with peptides for 24 hours 
in 1-ml total volume. Twenty-four hours later, medium was re-
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A-EJ reporter assay was performed according to (10) with some 
minor modifications. Specifically, U2OS EGFP-aEJ were seeded 
into six-well plates and siRNA transfected. Six hours later, cells 
were transfected with I-SceI expression plasmid (pCBA) using 
Fugene 6 (Promega). Medium was exchanged 24 hours after and 
replaced with 2-ml fresh medium and the peptides (10 M). Twenty- 
four hours later, medium was again replaced with fresh medium 
without peptides, and 72 hours after I-SceI transfection, cells were 
harvested. GFP expression (readout for HR and a-EJ frequency) was 
measured by flow cytometry using the Attune Nxt flow cytometer 
equipped with a 488-nm laser and 530/30 band-pass filter. A mini-
mum of 20,000 events were recorded.
DNA fiber analysis
DNA fiber analysis was carried out according to (7). U2OS cells were 
plated into six-well plates and incubated with 2 ml of medium/peptide 
mix. Twenty-four hours later, U2OS cells were labeled with 33 M 
CldU (Sigma-Aldrich) for 30 min, 340 M IdU (5′-iododeoxyuridine; 
Sigma-Aldrich) for 30 min, and followed by treatment with 2 mM 
HU (Sigma-Aldrich) for 4 hours. Cells were lysed [200 mM tris 
(pH 7.4), 50 mM EDTA, and 0.5% SDS], DNA was stretched onto glass 
slides, and fibers were fixed in MeOH:acetic acid (3:1). Rehydration 
with PBS was followed by denaturation with 2.5 M HCl for 1 hour 
and a PBS wash. DNA fibers were blocked in 2% bovine serum albumin 
and 0.1% Tween 20 (w/v) in PBS for 40 min. CldU/IdU tracks were 
immunostained using anti-BrdU primary and corresponding secondary 
antibodies for 2.5 hours each (see table S3). Coverslips were mounted 
using ProLong Gold Antifade Mountant (Life Technologies), and 
images were acquired on a Leica DM6 microscope, 63× objective. 
DNA fiber lengths were analyzed using Fiji software.
Clonogenic survival assay
Two hundred cells per well were seeded into poly-l-lysine (Sigma- 
Aldrich)–coated 24-well plates and the next day treated with respective 
drugs (CPT, Sigma-Aldrich; olaparib, Selleck Chemicals) and pep-
tides (total volume: 300 l per well). For details, see figure legends. 
After 10 days of growth, cells were fixed with crystal violet solution 
[0.5% crystal violet and 20% ethanol (w/v)]. Plates were scanned, 
and survival was analyzed with the ImageJ plugin Colony Area 
using the parameter colony intensity as readout (47).
Quantification and statistical analysis
Statistical analyses were performed using GraphPad Prism. Statistical 
tests are reported in the figure legends. If not indicated otherwise, 
each experiment was repeated at least three times. If the data con-
formed to a normal distribution, then an unpaired two-tailed t test 
was used. One-way analysis of variance (ANOVA) and Tukey’s 
multiple comparison test were used when comparing multiple 
groups with each other. Two-way ANOVA and Sidak’s multiple 
comparison test were applied to compare multiple groups of two 
factors. Fiber experiments were performed twice (n = 2), and rep-
resentative experiments are depicted. Samples were subjected to a 
Mann-Whitney analysis. P values of <0.05 were considered statistically 
significant. ns, not significant; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; 
****P ≤ 0.0001. Fluorescence polarization was fitted with nonlinear 
regression using the model Y = Bmax * Xh / (KDh + Xh), where bind-
ing at equilibrium by Bmax is the maximum specific binding, KD is 
the ligand concentration needed to achieve a half-maximum bind-
ing at equilibrium, and h is the Hill slope.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/8/eabc6381/DC1
View/request a protocol for this paper from Bio-protocol.
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